MedTrace Logo

Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis

NCT00573794 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 592

Last updated 2021-07-07

Study results available
· View outcomes & findings →

Summary

To assess the long-term safety and maintenance of response of adalimumab in subjects with ulcerative colitis who participated in and successfully completed M06-826 (NCT00385736) or M06-827 (NCT00408629).

Conditions

Interventions

BIOLOGICAL

adalimumab

adalimumab prefilled syringes administered as subcutaneous injection EW or EOW

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • AbbVie Inc · AbbVie

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-28
Primary Completion
2016-12-31
Completion
2016-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00573794 on ClinicalTrials.gov